title: [Study on the therapy of castration-resistant prostate cancer: randomized phase II study of abiraterone acetate plus LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naïve castration-resistant prostate cancer [SPARE - AP 67/11 of the Association of Urogenital Oncology (AUO)]].
authors.affiliation: Geschäftsstelle der AUO, MeckEvidence, Seestraße 11, 17252, Schwarz, Deutschland, AUO@MeckEvidence.de.
authors.forename: H
authors.initials: H
authors.lastname: Rexer
mesh_terms: D000069501:Abiraterone Acetate; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000736:Androstenes / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D005260:Female; D005858:Germany; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000736:Androstenes; D007987:Gonadotropin-Releasing Hormone; D000069501:Abiraterone Acetate